Back to discover
Drug

Ranibizumab

Established medicine
ResearchActive indication expansion
Also known as Byooviz, Cimerli, Lucentis, RBZ+2 more

Byooviz, Cimerli, Lucentis, RBZ, Susvimo, rhuFab V2.

RxNorm595060UNIIZL1R02VT79
1
Research papers
20
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Time Course of Resolution of Diabetic Macular Edema by Sustained Suppression of VEGF-A with the Port Delivery Platform with Ranibizumab

Industry2026-10-27American Journal of Ophthalmology

CHMP positive opinion: Fovlussea (EMA)

Regulatory2026-10-16EMA

Merck reports mixed data for Lucentis competitor in diabetic macular edema

Industry2026-10-12Endpoints News

Marketing authorisation: Susvimo (EMA)

Regulatory2026-09-18EMA

Label change: RANIBIZUMAB-NUNA (BLA761202)

Regulatory2026-09-01FDA

CHMP positive opinion: Susvimo (EMA)

Regulatory2026-07-24EMA

Biosimilar medicine authorisation: Vislyfa (EMA)

Regulatory2026-07-15EMA

Supplemental approval: RANIBIZUMAB-NUNA (BLA761202)

Regulatory2026-05-04FDA

Label change: RANIBIZUMAB-NUNA (BLA761202)

Regulatory2026-03-30FDA

Label change: RANIBIZUMAB-NUNA (BLA761202)

Regulatory2025-11-12FDA

Label change: RANIBIZUMAB-NUNA (BLA761202)

Regulatory2025-08-15FDA

Anti-Vascular Endothelial Growth Factors Protect Retinal Pigment Epithelium Cells Against Oxidation by Modulating Nitric Oxide Release and Autophagy.

Research2017-07-25De Cillà S · Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Ranibizumab
Aliases & brands
ByoovizCimerliLucentisRBZSusvimorhuFab V2
RxNorm CUI
595060
UNII
ZL1R02VT79
Regulatory jurisdictions
emafda

Regulatory timeline

20 events

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Approval / market entry confirmed across FDA and EMA (2026-05-04 → 2026-09-18)
Generic / biosimilar approval confirmed across FDA and EMA (2021-08-18 → 2022-11-09)
Earliest approval
2007-01-22
Latest approval
2026-09-18
Authorities
FDA · EMA
Total events
20
fdaU.S. Food and Drug Administration· 10 events
2026-09-01Label change
Label change: RANIBIZUMAB-NUNA (BLA761202)
Evidence ↗
2026-05-04Supplemental approvalMulti-authority
Supplemental approval: RANIBIZUMAB-NUNA (BLA761202)
Evidence ↗
2026-03-30Label change
Label change: RANIBIZUMAB-NUNA (BLA761202)
Evidence ↗
emaEuropean Medicines Agency· 10 events
2026-10-16CHMP positive opinion
CHMP positive opinion: Fovlussea (EMA)

Indication: Treatment of neovascular (wet) age-related macular degeneration (AMD), and other visual impairments in adults

Evidence ↗
2026-09-18Original application approvalMulti-authority
Marketing authorisation: Susvimo (EMA)
Indication: Susvimo is indicated in adult patients for the treatment of neovascular (wet) age-related macular degeneration (nAMD) who have achieved stable disease after previously responding… Show full indication

Susvimo is indicated in adult patients for the treatment of neovascular (wet) age-related macular degeneration (nAMD) who have achieved stable disease after previously responding to intravitreal treatment with a vascular endothelial growth factor (VEGF) inhibitor medicinal product.

Evidence ↗
2026-07-24CHMP positive opinion
CHMP positive opinion: Susvimo (EMA)

Indication: Treatment of adults with neovascular (wet) age-related macular degeneration (AMD).

Evidence ↗

Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

Research activity

1 paper

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Most influential

Anti-Vascular Endothelial Growth Factors Protect Retinal Pigment Epithelium Cells Against Oxidation by Modulating Nitric Oxide Release and Autophagy.

Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology · 2017 · 16 cites
Recent papers

Anti-Vascular Endothelial Growth Factors Protect Retinal Pigment Epithelium Cells Against Oxidation by Modulating Nitric Oxide Release and Autophagy.

Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology · 2017 · 16 cites
Journals, researchers & institutions
Top journals
  • Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology1
Leading researchers
  • Casini G1
  • Clemente N1
  • De Cillà S1
  • Farruggio S1
  • Filippini D1
  • Gatti V1
  • Grossini E1
  • Mary D1
Leading institutions
free-text, unnormalised
  • Eye Clinic1
  • University East Piedmont1
  • University of Pisa1

Related drugs

5 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Adenine

Frequently co-studied with Ranibizumab in the research literature.

1 shared paper
Aflibercept

Frequently co-studied with Ranibizumab in the research literature.

1 shared paper
Hydrogen Peroxide

Frequently co-studied with Ranibizumab in the research literature.

1 shared paper
Nitric Oxide

Frequently co-studied with Ranibizumab in the research literature.

1 shared paper
Sirolimus

Frequently co-studied with Ranibizumab in the research literature.

1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • Europe PMC — research literature
  • Regulatory event sources are credited in the Regulatory Timeline above.